Last update May 20, 2024

Τεραζοσίνη υδροχλωρική

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Alpha-1 adrenergic blocker used in the treatment of arterial hypertension and obstructive symptoms derived from benign prostatic hypertrophy. Oral administration once daily. 

At the time of the last update, we found no published data on its excretion in breast milk. 

Its pharmacokinetic data (moderately high molecular weight, very high percentage of protein binding, and high volume of distribution) make it unlikely that significant quantities will pass into milk. 

Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Anderson 2018, Malachias 2016), especially during the neonatal period and in case of prematurity.

Alternatives

  • Doxazosin Mesylate ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Finasteride (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Labetalol Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Methyldopa ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoprolol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nifedipine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nimodipine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Propranolol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Tamsulosin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Tradenames

Main tradenames from several countries containing Τεραζοσίνη υδροχλωρική in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 460 daltons
Protein Binding 94 %
VD 0.35 - 0.43 l/Kg
pKa 7.24 -
Tmax 1 - 2 hours
9 - 12 hours

References

  1. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  2. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  3. KPh. Terazosina. Ficha técnica. 2013 Full text (in our servers)
  4. Terazosin. Drug Summary. 2010 Full text (in our servers)

Total visits

1,507

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM